Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ON101 MOA Study in Diabetic Foot Ulcers
NCT04945161Completed
- Sponsor
- Oneness Biotech Co., Ltd.
- Start
- Feb 2021
- Primary completion
- Nov 2021
- Modality
- Botanical drug
- Countries
- 1
01
Overview
Randomised, double-blind trial in diabetic foot ulcer (DFU) comparing ON101 with Placebo (2 arms). Primary endpoint: Percentage change from baseline in the expression level of individual target gene(s). Started Feb 2021; status: completed.
02
Drugs
Fespixon
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT04945161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04945161.